PAR · —
NFL Biosciences SA (ALNFL.PA) Stock
$0.83
-4.60%
PAR: ALNFL.PA
—
—
Valuation
Financials & Margins
Latest News
Larry Robbins's Top Q2 2026 Move: Trimming CVS Health Corp at a -6.08% Portfolio Impact
GuruFocus.com · Aug 14, 2026
Stanley Druckenmiller's Bold Second Quarter 2026 Move: Slashing Alcoa Corp at a -2. ...
GuruFocus.com · Aug 14, 2026
Kultura Brands Establishes Authorized Share Ceiling and Next Phase of Capital Structure Reform
ACCESS Newswire · Aug 14, 2026
Louis Moore Bacon's Top Q2 2026 Move: Bank of America Corp at a -1.49% Portfolio Impact
GuruFocus.com · Aug 14, 2026
Manning & Napier Group, LLC's Top Second Quarter 2026 Move: Knight-Swift Transportation ...
GuruFocus.com · Aug 14, 2026
Valuation & Return Ratios
Ownership
Insiders Held14.21%
Institutions Held0.00%
Institutions Float Held0.00%
Peer Comparison
About NFL Biosciences SA
—
NFL Biosciences SA is led by CEO Bruno Lafont, employs 4 people, headquartered in Castelnau-le-Lez, FR, publicly traded since 2021.
NFL Biosciences SA (ALNFL.PA) stock trades at $0.83 with a market capitalization of $10.54M. The stock is valued at a price-to-earnings (P/E) ratio of -3.19, price-to-book of 34.67, price-to-sales of 56081.41. Over the past 52 weeks the stock has ranged between $0.80 and $1.85, and currently trades 55.1% below its 52-week high.
On profitability, NFL Biosciences SA generates a return on equity (ROE) of -517.39%, an operating margin of -5838226.60%, a net profit margin of 0.00%.
Official website: www.nflbiosciences.com